Arrowhead begins dosing in Phase 1 study of ARO-APOC3
Arrowhead Pharmaceuticals announced that it has dosed the first subjects in a Phase 1 clinical study of ARO-APOC3, an RNAi-based investigational medicine targeting Apolipoprotein C-III being developed for the treatment of hypertriglyceridemia.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.